HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Abstract
Emerging evidence indicates a link between the increased proportion of regulatory T cells (Tregs ) and reduced survival in patients who have been diagnosed with cancer. Cancer stem cells (CSCs) have been indicated to play a vital role in tumour initiation, drug resistance and recurrence. However, the relationship between Tregs and CSCs remains largely unknown. Here, we sorted out ovarian cancer stem-like side population (SP) cells and CD133+ cells to investigate the influence of ovarian CSCs on Tregs . Among the various immune-related molecules that we assessed, C-C motif chemokine ligand 5 (CCL5) was the most elevated in ovarian CSCs relative to that in the non-CSCs. The expression of its receptor, C-C motif chemokine receptor 5 (CCR5), was also increased on the surface of Tregs in ovarian cancer patients. This receptor-ligand expression profile indicated that ovarian CSCs recruit Tregs via CCL5-CCR5 interactions. We further assessed the expression of interleukin (IL)-10 in Tregs cultured with different cancer cells. Tregs cultured in conditioned medium (CM) from ovarian CD133+ cells expressed a higher level of IL-10 than Tregs cultured in CM from CD133- cells, indicating that Tregs exert pronounced immune-inhibitory functions in CSC-rich environments. Furthermore, co-culture with ovarian cancer cell lines induced the expression of matrix metalloproteinase-9 (MMP9) in Tregs which, in turn, enhanced the degradation of the extracellular matrix and enabled the invasion of tumour cells, thereby facilitating tumour metastasis. For the first time, to our knowledge, our findings describe the relationship between ovarian CSCs and Tregs , and demonstrated that these two cell populations co-operate to promote tumour immune tolerance and enhance tumour progression.
AuthorsY You, Y Li, M Li, M Lei, M Wu, Y Qu, Y Yuan, T Chen, H Jiang
JournalClinical and experimental immunology (Clin Exp Immunol) Vol. 191 Issue 1 Pg. 60-73 (01 2018) ISSN: 1365-2249 [Electronic] England
PMID28868628 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2017 British Society for Immunology.
Chemical References
  • Biomarkers
  • Chemokine CCL5
  • Matrix Metalloproteinase 9
Topics
  • Biomarkers
  • Case-Control Studies
  • Cell Line, Tumor
  • Chemokine CCL5 (metabolism)
  • Female
  • Gene Expression
  • Humans
  • Immune Privilege
  • Lymphocyte Activation (immunology)
  • Matrix Metalloproteinase 9 (genetics, metabolism)
  • Models, Biological
  • Neoplastic Stem Cells (immunology, metabolism)
  • Ovarian Neoplasms (immunology, metabolism, pathology)
  • T-Lymphocytes, Regulatory (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: